Pieris Pharmaceuticals, Inc.
PIRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $30,273 | $16,392 | $77,139 | $243,988 |
| - Cash | $83,602 | $17,396 | $38,635 | $117,764 |
| + Debt | $0 | $0 | $13,103 | $13,841 |
| Enterprise Value | -$53,329 | -$1,004 | $51,607 | $140,065 |
| Revenue | $0 | $42,810 | $25,902 | $31,418 |
| % Growth | -100% | 65.3% | -17.6% | – |
| Gross Profit | $0 | $1,009 | $23,122 | $29,050 |
| % Margin | – | 2.4% | 89.3% | 92.5% |
| EBITDA | $0 | -$22,762 | -$32,521 | -$45,778 |
| % Margin | – | -53.2% | -125.6% | -145.7% |
| Net Income | -$17,434 | -$24,543 | -$31,253 | -$43,366 |
| % Margin | – | -57.3% | -120.7% | -138% |
| EPS Diluted | -7.83 | -21.8 | -33.71 | -53.75 |
| % Growth | 64.1% | 35.3% | 37.3% | – |
| Operating Cash Flow | -$10,840 | -$53,819 | -$59,932 | -$7,660 |
| Capital Expenditures | $0 | -$171 | -$1,041 | -$949 |
| Free Cash Flow | -$10,840 | -$53,990 | -$60,973 | -$8,609 |